Genome & Company
4 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| A First-in-human Study of GENA-104A16 in Patients With Advanced Solid Tumors (NCT06235541) | Genome & Company | 2024-02-01 |
| GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer (NCT05998447) | Genome & Company | 2023-09-18 |
| GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer (NCT05419362) | Genome & Company | 2022-04-07 |
| GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy (NCT04601402) | Genome & Company | 2020-10-26 |
Track Genome & Company automatically
Every clearance here is in the API, with alerts when new ones post.